ãªãã³ãŒãã¹ VSLãšåºååæ
ãããªã¯å·ãã颚éªãæ¢ããããã«äœããã質åã§å§ãŸããŸã ãªã"å¥åŠãªãã³ã¯å¡©ã®ããªãã¯"ã äžæ¯ã ããã£ãŠ åé«ã女åªã« ãã€ãšãããéå,o...ãªãã§ã¯ 68æ¥ã§ 77ãã³ãç©ããããã®ã?
8,226+
Videos & Ads
+50-100
Fresh Daily
$29.90
Per Month
Full Access
12.5 TB database · 72+ niches · 29 min read
ãããªã¯"å€ãªãã³ã¯å¡©ã®ããªãã¯"ã飲ãã§ãã«ããã§ ãªãæåãªå¥³åªãé£äºãéå,è¬ãªã©ãªãã«68æ¥éã§ 77ããç©ããã®ã?ãšãã質åããå§ãŸããŸã. 芳è¡ãåæãè©äŸ¡ããæéããªãåã«,èªãæã¯èªå·±ç޹ä»ãã ãã¯ã¿ãŒã»ãããã³ã ãºãš ã¬ã³ããªãŒã. æ¬ç©ã®åºçç©ã è£çµŠåäŒç€Ÿãæã€æ¬ç©ã®å»åž«ã§ã æ©å¶ã説æã ãªãã©ã«ã»ãŠã£ã«ãœã³æ°åãåŒãã§ åãçµæãèŠãããããã«çŽæãã. ããã¯å¶ç¶ã®éãã§ã¯ãããŸãã. äœéæžå°ããŒã±ãã£ã³ã°ã«ãããæã匷åãª2ã€ã®åãå©çšããäºæž¬ãããèªç¥æµã®é害ã§ãã. å人ãžã®æ§ããšåé¡ã¯æ±ºããŠèŠèŽè ã®ããã§ã¯ãªããšããæç€ºãããçŽæã§ã. äœéæžå°ã«ãã»ã«è£çµŠåã§ãã LipoCorpus ã® VSL ã¯,ãã®éæãçŽæ¥åå¿ã®å¥åº·åéã§çŸåšæµéããŠãããã詳现ãªè²©å£²æžç°¡ã®äžã€ã®å ¥éç¹ãšããŠå±éããŠããŸã. ãã®ç¹å®ã® VSL ãæ·±ã調ã¹ã䟡å€ã¯ ã«ããŽãªãŒåºæºã§ç°åžžãªæ¬ºçæ§ãããããšã§ã¯ãªã,ããã§ã¯ãªã. ããã¯,çŸä»£ã®å¥åº·ã³ããŒã¹ã©ã€ãã£ã³ã°ã«ãããæã广çãªèª¬åŸæ§é ã®æçããæè¡çã«æŽç·Žãããåæã代衚ãããã®ã§,ãã®æ žå¿ç§åŠçãªäž»åŒµ (ããã©ã«ãšæ€ç©åŠçååç©ãèªç¶ã«ã€ã³ãžã§ã¯ã¿ãã«è¬ç©ã®ãã«ã¢ã³å¹æãåçŸã§ãã) ãåççã¡ã«ããºã ãšéå¡ãªæœåºæ§ã®éåžžã«ç¹å®ã®äº€å·®ç¹ã«ãã補åã®äžã«å±€æ¬¡åãããŠããŸã. çã®ç§åŠãå®åšããæ©é¢ ãããŠæ¬åœã®å ¬ã®äººç©ã䞻匵ã§ãããšããä¿¡ææ§ãåããŠ å€§å¹ ã«é²åŸ¡å¯èœãªããšããèšåºçã«äžå¯è§£ãªãã®ãŸã§ claimããŸã ãã®æ¬ã®éèŠãªåæèª²é¡ã¯ ãã®ç·ãã©ãã«èœã¡ããçè§£ããããšã§ã 補åèªäœã¯,åäžã®çéžããŒãžã§è²©å£²ãããæ¥çšå£æã«ãã»ã«ã§ãã,ã»ãã°ã«ãŒãã (ãªãŒã³ãã¯) ãšãã£ã«ããã¿ã€ã (ã ãŠã³ãžã£ã) ã®ãããªæ³šå°å¯èœãªGLP-1å容å€ã¢ãŽãã¹ãã«å¯Ÿããèªç¶ãªä»£æ¿ãšããŠäœçœ®ã¥ããããŠããŸã. 身äœã®èªå·±çç£ãåºæ¿ãããšããä»çµã¿ã¯ ãã¿ã·ãŠã ,ãã°ããžã¢ã ,ç·è¶æœåºç© 氎溶åã³ã©ãŒã²ã³ãšãã«ã¡ãªãã¯ãæŠå¿µçãªã¬ãã«ã§ æ¬ç©ã®å åæ³åŠã«åºç€ã眮ããŠãã. ãã®æŠå¿µçãªåºç€ãã VSL ã§æåºãããå ·äœçãªçµæäž»åŒµãžã®è·³èºã¯,ããããæœåšçãªè³Œå ¥è ã«ãšã£ãŠå³æ Œãªåæãäžå¯æ¬ ã«ãªã. ãã®åè§£ã§ã¯, VSL ã¯è£œåææžãšèª¬åŸåšå ·ã®äž¡æ¹ã§æ€èšãããŸã. 調ã¹ãŠãã質åã¯åçŽã§ã. ãªãã³ãŒãã¹ã®è²©å£²æžç°¡ã§å®éã«äž»åŒµãããŠããã®ã¯,ãã®ãã¡ã©ããç¬ç«ç§åŠã«ãã£ãŠè£ä»ããããŠããã®ã,ããã¯èšè«çãªæ§é ã§ãã,ãã®ãããã®å šäœåã§ã¯èª°ãæ¬ç©ãäœã£ãŠãããã«ã€ããŠäœãæããã«ãªã£ãŠããã®ã§ãããã? ##ãªãã³ã«ãã¹ã¯äœã§ãã? ã©ã€ãã«ã«ãã¹ ã¯é£çšãµããªã¡ã³ããšããŠã«ããã»ã«åœ¢åŒã«å£²ãããŠããŠäž»ã«35æ³ãã65æ³ã®å¥³æ§åãã«è²©å£²ãããŠããŸã. äœçœ®ä»ãã¯,GLP-1å容å€ã¢ãŽãã¹ãè¬ã®äž»æµäººæ°ã«ãã£ãŠäœãããã«ããŽãªãŒã«æç¢ºã«å«ãŸããŠããŸã.OzempicãšMounjaroãå«ãã¯ã©ã¹ã§ãã,ãã®ã«ããŽãªå ã®"èªç¶ä»£æ¿å"ã¬ãŒã³ãå ããŠããŸã. 補åã¯,ç±³åœã§FDAã«ç»é²ããGMPèªèšŒãåããæœèšã«ãã㊠VSL ã«åºã¥ããŠè£œé ãããŠãã,æ¥æ¬è£œè¬äŒç€ŸNotori Labsãšã®ææºã«ãã調éãããæåã䜿çšããŠããŸã. 販売ã¯ã¢ããŸã³,GNCãŸãã¯å°å£²è¬å±ãã§ãŒã³ã§ã¯ãªãç¬èªã®ã©ã³ãã£ã³ã°ããŒãžãéããŠã®ã¿è¡ãããŸã. ããã¯ç瞮信å·ã§ããçŽæ¥å¿çã®ããŒã±ãã£ã³ã°æšæºã®äž¡æ¹ã§ããé ééžæã§ã. è£çµŠå€ã®é æ¹ã«ã¯4ã€ã®æŽ»æ§æåãå«ãŸããŠãããšèª¬æãããŠããŸã:ãã³ã¯è²ã®ããã©ã€å¡©ããåŸãããã«ãªãŠã ããã³ãã°ãã·ãŠã ã¯,æ¥æ¬ã®ç·è¶æœåºåã¯,ã¢ã»ãã©ããã®ãã¿ãã³Cã䜵çšããã¿ã€ã1åæ°Žååã³ã©ãŒã²ã³ã§ãã,ãããªã³ (é»ãäžã®æå¹ååç©) ãšçµã¿åãããã«ã¡ãªã§ã. VSLã¯ããã"4ã€ã®æåã®ã·ããŒãžã¹ã¿ãã¯"ãšããŠå®çŸ©ã,åæ§æèŠçŽ ãç°ãªã圹å²ãæãã. é±ç©ã«ãã£ãŠGLP-1ãšGIPãã«ã¢ã³çç£ã掻æ§åãããã,ç·è¶ã«ãããã®æŽ»æ§ã匷åããç¶æããã. é«è質ã³ã©ãŒã²ã³è€åäœã¯çŽ æ©ãäœéæžå°ããéã«ç®èã®æŽäœãä¿è·ããŸã. ã«ã«ã¡ãªãã¯-ãã€ããªã³ã®çµã¿åããã§ã¯è žççæå¶ãããŸã. ãã以å€ã®å Žåã¯ãã«ã¢ã³ãåãããã¯ããã§ããã. ã«ãã»ã«ãã©ãŒãããã¯,æäžç²ŸåºŠã®ããã«ç²æ«ãè¶ãããæç¢ºã«ä¿è·ãããŠããŸã. åžå Žããžã·ã§ãã³ã°ã«é¢ããŠã¯,ãªãã³ãŒãã¹ã¯åæ³çãªæ é€ç£æ¥çãšå€éæ å ±åºåãæŽå²çã«éããçŽæ¥åå¿ãµããªã¡ã³ãã«ããŽãªãŒéã®ç©ºéã«äœçœ®ããŠããŸã. ãã©ã³ãã¯çŸä»£çã§,GLP-1ã¡ã«ããºã ãçŸåšã®èšåºç§åŠã§ãã,Ozempic/Mounjaroåç §ã¯2024-2025å¹Žã«æåçã«å ±é³ŽããŠããŸã. ããã,ãã®è£ã«ãã販売æ§é ã¯ãã«ã¢ã³çæ³ãšä»£è¬å»åŠã®èªåœã«è£ çãã äœå幎ãã®çŽæçãªæ§é ã§ã. ç®æšãšãªãåé¡ã¯ãªãã³ãŒãã¹ã®ã¿ãŒã²ããã§ããã®ã¯åã«è¥æºã§ã¯ãããŸãã. äŒçµ±çãªæžéæ¹æ³ã詊ãã人ã®äžæºã§ã. ã«ããªãŒå¶é éåã忥çãªãã€ãšããããã°ã©ã ãããŠå€±æãŸãã¯äžæçæåãçµéšã éæž©äœéå¢å ãç¶ããŸãã ããã¯äžè¬çãªéäœéäžæºãšã¯ 極ããŠç°ãªãå¿çç¶æ ã§ãã VSL ã¯ç°åžžãªç²ŸåºŠã§å¯ŸåŠããŸã. æŒå¥äŒ ã® éå¹ ã¯,çŽæ ã§ ãã ããš ã ãªã.ãã 㯠äŒè¡ 㫠察ãã äžæå ç ãªçµéš ã æçã«èšŒæ ãã ãã® ã§ã.ãã® ãã 㪠èšè ãã "ãã ãã¹ãŠ ã® çœª 㯠ããªã ã® ãã ã§ ãã ãŸã ã".ãšãã èšãèš³ã æãéã ãŸã.ãã® èªå¥ã¯å¶ç¶ã§ã¯ãªã,説åŸå ã® å šäœ ã ãã® äžãåãææ ç éç¹ ãš ãªã ㊠ã ãŸã. VSLãåŒã³åºãæµè¡ç åŠçãªèæ¯ã¯çŸå®çã§ã. äžçè¥æºé£çã«ãããš 1970幎代以é çºå±éäžåœã§ã¯ å€§å¹ ã«å¢å ããŠããŸã 2030幎ãŸã§ã« çŽ10å人ãè¥æºã§æ®ãããšäºæž¬ãããŠããŸã CDCã¯æè¿è¡ãããå šåœå¥åº·ãšæ é€èª¿æ»ã§ æäººã®è¥æºçã41.9%ã«éãããšå ±åããŠããŸã. ãããã®åŸåã¯,人å£ã¬ãã«ã§ã®çã®æµãã§ãã,VSL ã¯ããããåŒçšãã確åºãããã®ã§ããã,éžæçã«ãããåç §ã,åé¡ã®èŠæš¡ã䜿çšããŠåå ã®è€éããæèåããã®ã§ã¯ãªã解決ã®ç·æ¥æ§ãåçã«è¡šçŸããŸã. è¥æºãå¢å ã,è¶ å å·¥é£åæ·»å ç©ã«ããGLP-1ããã³GIPçç£ã®æžå°ã«ã€ã㊠VSLã¯ææ¡ããŠããã¡ã«ããºã ãšã¯ æ¬åœã«è€éãªä»£è¬çãªã€ã¡ãŒãžãå€§å¹ ã«ç°¡çŽ åããŠããŸã. ã€ã³ã¯ã¬ãã³ (GLP-1 ãš GIP ã å±ãã ãã«ã¢ã³ å®¶æ) ã® ç§åŠ ã¯ ãã ç¥ãããŠããŸã. äž¡ãã«ã¢ã³ã¯ é£ã¹ç©ã®æå ã«å¿ããŠè ž ã§ çã¿åºãã,ã€ã³ã¹ãªã³ åæ³ ãè 空ã åé£ä¿¡å· ã 瀺ã ㊠ãã ããš ã æå ã§ã. ç³å°¿ç ã±ã¢ ãš ãã¥ãŒã€ã³ã°ã©ã³ããžã£ãŒãã«ã»ãªãã»ã¡ãã£ã·ã³ ãªã©èªã«æ²èŒãããç ç©¶ã«ãããš,ãã®çµè·¯ãå©çšããããšã§ GLP-1 å容åšã¢ãŽãã¹ãè¬ãææçŸ©ãªäœéæžå°ãããããããšã確èªãããŠããŸã. ãã®åºç€ãã VSLãæœåºããŠããã®ã¯ çŸä»£é£åæ·»å ç©ã "ã»ãŒæé€"ããããšã§ã ã¢ã¡ãªã«äººã®äœå ã®ãã«ã¢ã³ã§ã è¥æºã®æµè¡ã説æããã®ã¯ãã®æ¬ é¥ã ãã§ã ãã㯠åé¡ã¬ãã¥ãŒãããæç®ã§ã¯ ãã®åœ¢ã§æ¯æãããŠããªãèšèª¬çãªãžã£ã³ããªã®ã§ã 忥çãªæ©äŒã¯,å®éã«åºå€§ã§ã. å»è¬åæ¥çå ±åã«ãããš,GLP-1è¬åžå Žã§ã¯2024幎ã«çŽ10å5åäžåã®åçãäžããŸãã.ãã®ã¯ã©ã¹ã§å©çãåŸã人å£ã®éèŠãªéšåã¯ããããè²·ããããšãã§ããªããå¯äœçšãæžå¿µãããã®ããŸãã¯åŠæ¹å»ãžã®ã¢ã¯ã»ã¹ããªãã®ã§ã. ååã®ã¡ã«ããºã ãæé»ã«åºæºå¯Ÿè±¡ãšãªãè¬é¡ãšäžèŽãããã©ããã«é¢ä¿ãªã,忥çã«åççãªããžã·ã§ãã³ã°æŠç¥ãšã㊠ãã®æªæºããããéèŠã«å¯Ÿããã¢ã¯ã»ã¹å¯èœã§æé ãªäŸ¡æ Œã§ã®å¯äœçšã®ãªãçããšããŠã®ç«å Žã確ç«ããŠããŸã. > ãã®ãããå ã®ä»ã® VSLs ãã©ã®ããã«ããŒãæ§é ãããŠãããäžæè°ã§ã? èªã¿ç¶ãã. [ããã¯åæ] (#ããŒã¯ãšã¢ãã¢ã³ã°ã«) ãš[å¿çæŠè¡ã»ã¯ã·ã§ã³] (#å¿çåŠè§Šçºè ã»èª¬åŸåæŠç¥) ã¯,ããã§è¡ãããŠããå ·äœçãªåããåè§£ããŸã. ##ãªãã³ãŒãã¹ã®ä»çµã¿ VSLãææ¡ããã¡ã«ããºã ã¯3段éã«åãããŠããŸã. ãŸã,䞻匵㯠35æ³ä»¥äžã®ã»ãšãã©ã®äººã è žå ã«ããããã«ã¢ã³çç£çµè·¯ãé»å®³ããè¶ å å·¥é£åæ·»å ç©ã«å¯Ÿããèåãšæ ¢æ§çãªæŽé²ã®çµã¿åããã«ãã GLP-1ããã³GIPã¬ãã«ãåçã«äœäžããŠãããšããããšã§ã. å ¬åŒã®éèŠãªããã©ã«ã§ã. ãã³ã¯ã®ããã©ã€å¡©ããåŸãããã«ãªãŠã ãšãã°ãã·ãŠã ã¯,è žå ç¥çµäŒéç©è³ªã®ãããªååç©ãšããŠäœçšã,GLP-1ããã³ GIPãèªç¶ã«çæããå容äœã掻æ§åãããšäž»åŒµãããŠããŸã. 第äžã«æ€ç©åŒ·åå€ (ç·è¶ã®æœåº,ãããªã³ä»ãã«ã¡) ã¯ãã«ã¢ã³æŽ»æ§åãç¶æãæ·±ã Kolagenè€åäœã¯ç®èãä¿å šããã®ã§èèªãæ¥éã«æžå°ããŸã ç§åŠçãªæç®ãå®éã«æ¯æããŠããããšãšæ¯ã¹ããš ãã®ããšãåè§£ããŸã GLP-1 ãš GIP ã¯æ¬åœã«éèŠãªã€ã³ã¯ã¬ãã³ãã«ã¢ã³ã§ãã 飿¬²ã®å¶åŸ¡ãä»£è¬æ©èœã«ããã圹å²ã¯ ããèšé²ãããŠããŸã. è¶ å å·¥é£åã®æåãšå¹Žéœ¢ãšãšãã«GLP-1ã¬ãã«ãäœäžãããšãã䞻匵ã¯,çç©åŠç確çã¯ããçšåºŠé«ããŠ,æ ¢æ§ççããã³äžçèç ã«ãã£ãŠè žãã«ã¢ã³ä¿¡å·ãæãªãããšãç¥ãããŠãã. ãããVSLã§ã¯ããã¯,99.9%ã®äººå£ã«åœ±é¿ãäžããã»ãŒæ®éç㪠ã»ãŒç·æ¬ é¥ãšããŠè¡šèšãããŠãã" ããã¯èšåºèšŒæ ãã倧ããç°ãªã£ãŠããŸã. GLP-1ã¬ãã«ã¯åäœã«ãã£ãŠå€§ããç°ãªããŸã é£äºæå,è žå 埮çç©ã®å¥åº·,èº«äœæŽ»åããã³ã€ã³ã¹ãªã³æææ§ãªã©ã«ãã圱é¿ãåããŸã. ãšãã°ãã·ãŠã ã«é¢ããå ·äœçãªäž»åŒµã¯ ããæ€èšãããã¹ãã§ã. äž¡é±ç©ã¯ä»£è¬æ©èœã«ãšã£ãŠéèŠã§ãã,ç¹ã«ãã°ãã·ãŠã äžè¶³ã¯è¥¿æŽäººã®éã§æ¬åœã«äžè¬çã§ã NIHã®æ é€è£çµŠå±ã«ãããš ã¢ã¡ãªã«åœæ°ã®ããªãã®å²åãæ¯æ¥å¿ èŠãªãã°ããžã ã®éãæºãããŠããªããšæšå®ãããŠããŸã. ååãªãã°ãã·ãŠã ç¶æ ã¯ã€ã³ã¹ãªã³æææ§ãšè žãã«ã¢ã³ä¿¡å·ã®ããã€ãã®åŽé¢ããµããŒãããããšã瀺åããäºåç ç©¶ããããŸã. ããã,ã«ãªãŠã ã¯"GLP-1ãæå€§182%å¢å ãã",ãã°ãã·ãŠã ã"GDPã144%ãŸã§äžæãããå¯èœæ§ããããšãã䞻匵ã¯,åçã¬ãã¥ãŒè©ŠéšããåŸãããããã«æç€ºãããæ°åã§,ãããã®æ£ç¢ºãªæ°å€ãå«ãç¹å®ã®å ¬è¡šç ç©¶ã«èå¥å¯èœãªåŒçšããªã VSL ã«åºãŠãã. æ¹åæ§çã«åççãªã¡ã«ããºã ã§ãã,ç¹å®ã®éåã¯ã¬ã³ãŒãã£ã³ã°ããæ€èšŒã§ããªã. å šäœã®VSLã«ãããŠæãéèŠãªç§åŠçé£èºã¯,ãã®å£æé æ¹ãMounjaroã«çžåœãã广ãç£ã¿åºããšãã䞻匵ã§ãã. ãããã¯ãããããåªããçµæããããããšãã䞻匵ã§ã. ãã«ãŒããã (ã ã³ãžã£ã) ã¯,é«ç¹ç°æ§ããã³èŠªå¯æ§ã®é«ãGLP-1ãšGIPå容äœã«çŽæ¥çµåããããšã§å¹æãéæã,çŸåšææžåãããçµè·¯ãéããŠé£äºåé§å€ã®ã¿ã§éæã§ããªãæç¶çãªãã«ã¢ã³ä¿¡å·ãçºçãããŠããŸã. é±ç©ããã³æ€ç©æåãå«ãæ¥ã ã®ã«ãã»ã«ãå容äœã¬ãã«ã®åæã¢ãŽãã¹ãã®è¬ååŠååãè€è£œã§ãããšããèãã¯,çŸåšã®èšåºèšŒæ ã«ãã£ãŠæ¯æãããŠããŸãã. ããã¯é£æ¬²ã代è¬ã«åœ±é¿ããªãããšãæå³ããŸãã ãããã®æåã®äžã«ã¯ æ£åœãªç ç©¶ãæ¯ãããã®ããããŸã. ããã,ç䟡䞻匵ã¯éå¡ãªèšŒæ ãå¿ èŠãšãããããªç°äŸçãªæèšã§ãã,VSL ã¯ç¬ç«çã«æ€èšŒã§ãããã®ã¯äœãæäŸããŠããªã. ## ããŒã€ã³ãžãã³ã/ã³ã³ããŒãã³ã VSL ã§ã¯4ã€ã®æåã®å ¬åŒãèšè¿°ãã,åèŠçŽ ã«ç¹å®ã®æ©èœç圹å²ããã. ãã¬ãŒã ã¯ç¬ç«æåã§ã¯ãªãçžäºäŸåã®å¢åŒ·è£ 眮ã§ãããšããããšã§ã. "ãšã³ãžã³ãšçæ"ãšããæ¯å©ã¯æç€ºçã«çšããããŠããŸã. ç¬ç«æåŠã¯ããããã«ã€ããŠæ¬¡ã®ããã«è¿°ã¹ãŠãã. - ãã¿ã·ãŠã ãšãã°ããžã¢ã (ãã³ã¯ããã©ã€å¡©ãã): ãããã¯å ¬åŒã®æ žå¿ã§ãããšäž»åŒµããã¡ã«ããºã ã§ã. ã¯ãã°ãã·ãŠã ãšã«ãªãŠã ã®çè·¡ãå«ãã§ããŸãã,ãã®æ¿åºŠã¯ä»£è¬ç ç©¶ã§èª¿ã¹ãæ²»ççšéãšæ¯èŒããŠäœãã®ã§ã. ãã°ãã·ãŠã ã®ã€ã³ã¹ãªã³æææ§ãšä»£è¬å¥åº·ã«ããã圹å²ã¯, Nutrients (de Baaij et al., 2015) ã«æ²èŒãããç ç©¶ãå«ãè€æ°ã®ã¬ãã¥ãŒã«ãã£ãŠæ¯æãããŠããŸã. VSLã®ç¹å®ã®äž»åŒµã¯,ãã182%GLP-1å¢å ãšãã°ãã·ãŠã ããã®144% GIPäžæã«ã€ããŠãããã®ãã©ã¡ãŒã¿ã§ååå¯èœãªç ç©¶ã¯ãªã. 代è¬å¥åº·ãæ¯ããã®ã«ååãªãã°ãã·ãŠã ç¶æ ã¯,é²è¡å¯èœã§ãã.è¬å€ãšåçã®åŒ·åºŠã§ç ã£ãŠããé£œåæ§ãã«ã¢ã³ã掻æ§åãããããšã¯ç¢ºç«ãããŠããªã. - **æ¥æ¬ç·è¶æœåº (EGCG):ã°ãªãŒã³ãã£ãŒæœåºç©,ç¹ã«ãã®ã«ããã³ã®å«é (ãšããããšãã¬ãã±ãã³ã®ã£ã©ãŒã, EGCG) ã¯,æçŸ©ããç ç©¶ã«æ¯ããããŠãã. ã¢ã¡ãªã«ã³ãžã£ãŒãã«ã»ãªãã¯ãªãã«ã«ãã¥ãŒããªã·ã§ã³ (Hursel et al., 2009) ã« æ²èŒ ã ã ã ã¡ã¿è§£æ ã§,ç·è¶ ã«ããã³ã® äœéé ãšèèªé žå äž ã® æå®³ æ§ ã äžå° ãªããçµ±èš ç 㫠倧å ã 㣠㊠ã ãŸã. "è ¹ã®èèªãåå¢ãã"ãšãã䞻匵ã¯,å ¥æå¯èœãªèšŒæ ã«å€§ããèªåŒµãããŠããã,ãã®æåãä»£è¬æ¯æŽé æ¹ã«å ¥ããã®ã¯ç§åŠçã«æè·ã§ãã. - Acerola ãã¿ãã³Cãå«ã1åæ°Žååã³ã©ãŒã²ã³: æ°Žæ§åãããã³ãã©ã²ã³ã®è£çµŠã«ã¯ç®èåŒŸåæ§ãšç®è³ªåãã®ç ç©¶æ¯æããã. ã¹ãã³ã»ãã¡ã«ãã³ããžãŒãšççåŠ (Proksch et al., 2014) ã§çºè¡šãããã©ã³ãã åå¶åŸ¡è©Šéšã§ã¯,æ¯æ¥2.5-5g ã®ã³ãã²ã³ã®ããããã§ç®èã®åŒŸæ§æ¹åãèŠãããŸãã. JAMAã®ç ç©¶ã«é¢é£ä»ãããã"ã³ã©ãŒã²ã³ãšãšã©ã¹ãã£ã³ã®çç£éã®6åå¢å "ãšããå ·äœçãªäž»åŒµã¯,ãã®èšè¿°ã«å¯Ÿå¿ããJAMA詊éšã§å ¬è¡šããããã®ã«ã¯è¿œæº¯ã§ããªã. ã³ã©ãŒã²ã³åæãæ¯ããããã«ãã¿ãã³Cã®å«ãã¯,çç©ååŠã確ç«ãããŠãã. - [ã«ãã¡ãªã¯](/ããã° /ã¬ãã¥ãŒ/ã«ãã¡ãªãŒã¯-ããã©ã€ã»ããããããªãã¯-ç·æ§åŒ·åvslåæ) ãã€ããŒãªã³ (ã¯ã«ãã¥ãã³ãšãã€ãªããªã³): ããã¯å ¬åŒã§æãç§åŠçã«æ ¹æ ã®ããæåã§ã. ç®ããªã³ã¯ã«ãŒãã¥ãã³ã®çç©å©çšæ§ãåçã«å¢å ããããšã®çºèŠã¯, VSL ã¯,2000%ãåŒçšã, Planta Medicaã§çºè¡šããã"ã·ã§ãã»ãšããŒã« (1998) "ã®ç ç©¶ã«èšåããŠãã. ããã¯çŸå®çã§é »ç¹ã«ç¹°ãè¿ãããçµæã§ã. ãã¥ã«ã¯ãã³ã®æçæ§ç©è³ªã¯ æ°çŸãã®ç ç©¶ã§ãã蚌æãããŠããŸã. "ãã«ã¢ã³å容äœãããã¯ãæžãã"ã«ãã£ãŠäœéå¢å ã®äºé²ã«ç¿»èš³ããããã©ãã,ããã¯åççãªã¡ã«ããºã 仮説ã§ããèšåºçã«èšŒæãããçµæã§ã¯ãããŸãã. ## ããã¯ãšåºåè§åºŠ äž»ãªããã¯ã¯",ãªããã®å¥åŠãªãã³ã¯å¡©ããªãã¯ã§æ¯æ¥äžæ¯é£²ãã ããšã§ ãªãã©ã«ã»ãŠã£ã«ãœã³ã¯ãã€ãšãããéåããªããªã æããé£åãã諊ããªãã ãã§ããã68æ¥ã§77ãã³ãç©ããã®ã?"ãšããæç§æžäŸã§ã ãšãŠãžãŒã³ ã·ã¥ã¯ã«ãã¹ã¯ãããæ¬¡ã®ããã«åé¡ããŸã: åžå ŽæŽç·Žã®4段éãŸãã¯5æãžã®åã. äœéæžå°è£çµŠã®èŠèŽè ã¯çŽæ¥çãªã¡ã«ããºã ("èèªãçŽ æ©ãçãã") ãš,å©ç䞻匵 ("30ãã³ãæžéãã) "ãšèšŒèšè«æ±ã«é£œåããŠããŸã. åžå Žæèã®ãã®æ®µéã§ã¯,æ°ããããã¯ã¯æå€ãªã¡ã«ããºã ã«èµ·å ãã説æã§ããªãçµæãäžå¿ãšããŠæ§ç¯ããã 奜å¥å¿ã®ã£ãã ãå¿ èŠãšãã. "å€ãªãã³ã¯å¡©ã®ããªãã¯"ãšãã衚çŸã¯ 粟å¯ãªåããããŸã. "å¥åŠ"ãšã¯æ°å¥æ§ãšåçŽæçãªç¥èã瀺åãããã®ã§ã. "ç²è²ã®å¡©" ã¯èŠèŠåã§ããã»ã©å ·äœçã§ãã 説æãæ±ããããಷà³à²à³ç¥ç§çã§ã. å人åã«ã¯,å³åº§ã«ç€ŸäŒç蚌æ ãšãã©ãœã·ã¢ã«ä¿¡é Œæ§ããããŸã. ããã¯å¶ç¶ã®å»ºç¯ã§ã¯ãªã ã¬ãªãŒã»ãã«ããŒã"å°ããªç§å¯"ã æžãåºãçŽã ãã³ã»ãã㫠以å€ã®èšäºã«èŒãããã ã³ããŒã®äŒçµ±ã®çµæã§ã ã¯ãŸã open loop (Zeigarnik广ã¢ããªã±ãŒã·ã§ã³) ãšããŠæ©èœã,ãã®è³ªåã«ã¯ãããªãèŠãã«çããããªã.ãããŠéåžžã«é·ããã¬ãŒã³ããŒã·ã§ã³ã®æåã®3åã®1ã«çãã¯é ãããŠããŸã. ä»çµã¿ãæããã«ãããåã«å°å ¥ããããã¹ãŠã®ãµãããã¯ã¯ "æ¯æ¥ãªãŒã³ãã¯ãæçšããŠããããã«æããŸãã" 1980幎代ã«èº«äœå ã®äœããæ©èœããªããªã£ãã®ã§ã è£œè¬æ¥çã¯ãã®ã«ãŒããç¶æã㊠ãã®èœãšã穎ãé²ãããã«åœ¹ç«ã£ãŠããŸã. æ§é ã¯æå³çã§ã åæ°ããéšåæ å ±ãã æ°ãã質åãéãéã«èŠèŽè ãé¢ããããããã ãã®å¥œå¥å¿ãæºãã埮å°è§£åãäœãããŸã VSL ã§èŠ³æž¬ãããæ¬¡èŠãªããã¯ã«ã¯, - "ããªãã®äœã¯ãããã¯ã¢ãŒãã«å ¥ããŸãã. "åãç ç©¶ã ã ã³ãžã£ãã®éçºã§åŒçšããã" - "ç§ã¯ãã®èª¿æ»ãæžã,éèªã«æåºããŸãã. è¬å€ã¹ãã³ãµãŒã®ããã§æåŠãããŸãã "ãã®ããšã«ã€ããŠä»æ¥çªçµã®äžç¯ã¯è£œè¬äŒç€Ÿã®æ³åŸããŒã ãçŠæ¢ããŸãã" - "72ç¶ããæ®ãã,åŸ ã¡ãªã¹ãã«ã¯200äžäººããŸã". MetaãYouTubeã§ã¯ãªãšã€ãã£ãããã¹ãããã¡ãã£ã¢è³Œå ¥è ã«ãšã£ãŠ æ¬¡ã®èŠåºãå€ç°ã VSL ã®æã匷åãªè§åºŠã瀺ããŠããŸã. -- "圌女ã¯5é±ééã§48ãã³ãç©ãã. 泚å°ã¯äžèŠã§ã. éåå Žã¯ãªã. "ã¢ã³ãžã£ãã¯ãã«ã¢ã³2ã€ã§å¹ã" è¬å€äŒç€Ÿã¯ãã®ãããªãæ®ã£ãŠã¿ãŸãã. "ããã¯,å¥åº·çãªé£åã§ã"ãšã³ã¡ã³ãããŸãã. "35幎åŸã®ãã€ãšããããªã倱æããã®ã å»è ã¯æããŠãããªã" - "ãã³ã¯å¡©ãš3ã€ã®æçæå:å»åž«ã«èª¬æããããŠã€ã«ã¹ã«ããäœéæžå°æ¹æ³". ##å¿ççèªçºããã³èª¬åŸçç¥ ãã®VSLã®èª¬åŸæ¶æ§ã¯äžŠè¡çã«å®è¡ãããç°¡åãªããªãã¯ã®äžèЧã§ã¯ãããŸãã. å¿çåŠçã¡ã«ããºã ãæ¬¡ã®ããã®åºç€ãæºåããæ§é ã§ã. æçŽã¯ç€ŸäŒçãªèšŒæ (ã¬ãã«ã»ãŠã£ã«ãœã³ã®çµæ) ã§éãã,欲æ±ãšå¥œå¥å¿ãçã¿åºã ãã®åŸå ±æãè²¬ãæ¯ã ("ãããã¹ãŠããªãã®ããã§ã¯ãããŸãã") ã«è»¢æã,ææ çå®å šæ§ãæ§ç¯ããŸã. ãããŠç§åŠçã«èª¬æãããšèŠæ¹è ããã§ã«æ ç·ã§æºåãã§ããŠããæ±ºæãåçåããŠããŸã. ååã¯3段éã®ææ ãšèªç¥èšå®ã®åŸã§ çŸããŸã èŠãŠãã人ãç¥ããªããã¡ã«åŸ ã£ãŠãããã®ãšããŠã§ã¯ãªã売ããç©ãšããŠäœçœ®ã¥ããããŠããŸã ãã®ã·ãŒã±ã³ã·ã³ã°ã¯ ã·ã¢ã«ãã£ãã "èªæåã®å»ºç¯"ãšããŠèšè¿°ãããã®ã§ã åæã®æ¡ä»¶ã¯,èŠæ±ãããåã«èšå®ãããŸã. äœçŽã®ç«¶äºçžæãã ãã®3ã€ãåºå¥ããã®ã¯,ãã®åœæµæ§é ãè€éã§ããããšã§ã. ã»ãšãã©ã®ãµããªã¡ã³ãã¯äžéæãªæªåœ¹ãæå®ãã ("ãã€ãšããæ¥ç", "ããã°ã»ãã¡ãŒã"ãªã©). ãã®1ã€ã¯,ç¹å®ã®æŽå²çã«æ ¹æ ã®ããæªåœ¹ (ãã«ãŒãã¿ã€ããšã»ãã°ã«ãŒãã£ããã®è£œè¬ã¡ãŒã«ãŒ) ãå²ãåœãŠãŠãã,財æ¿çã«ã¯äžè²«ããåæ©ãæç€ºããŠããŸã. 幎éåå ¥ã¯10åãã«ã§ã. ãããŠå ·äœçãªæå§çãªç©èªãæäŸããŠããã®ã§ã. ãããã®äž»åŒµã¯ã©ããæ€èšŒã§ããªããã®ã§ æ§é çã«ããããããã«èšèšãããŠããŸãã ãã®ç¹æ§ã¯ äžæãªé°è¬ã®æ çµã¿ã«ã¯ãªããããªä¿¡é Œæ§ãäžããŸã 詳现ãçãèŠèŽè 㯠3ã€ãäžããã ãã®çޝç©çãªå¹æã¯ åã ã®èŠçŽ ãæ ¹æ ã®ãªãå Žåã§ãè£ä»ããããŠãããããªé°è¬ã®æ çµã¿ã§ã. ç¹å®æŠè¡éšçœ²ãã«ã¿ãã°ã«ãã¹ã: - Cialdiniã®æ©é¢ (ç©ã¿éããŠåãã): Dr. æ€èšŒã§ããªã䞻匵 (ã¯ãªã³ãã³é¡§å ãªã¿ã¯æ©èœå»åŠèšç·Ž) ãšãšãã«,ã°ã©ã³ããªãŒã®åæ³çãªè³æ ŒèšŒææžã æ¬ç©ã®æ¬ç©,å®éã®ã¡ãã£ã¢åºæŒ,æ¬ç©ã®ãµããªã¡ã³ãäŒç€Ÿãæç€ºãããŠããŸã. ãã广ã¯,å®éã®èªèšŒãæ€èšŒã§ããªããã®ã«ãä¿¡é Œæ§ãæ¡å€§ããããšãæå³ããŸã. - ãã§ã¹ãã£ã³ã¬ãŒã®èªç¥ç°å/ã¢ã€ãã³ãã£ãã£è åš: VSL ã¯ç¹°ãè¿ã芳客ã®çŸåšã®ç¶æ ãå åšçã«åŠå®çãªèšèã§èšè¿°ã ("ããªãã¯èªåã®äœã®å人ã ã£ã") ãããŠãã®è§£åãšããŠãªãã³ãŒãã¹ãæäŸããŸã. çŸåšã®èªå·±ãšæãŸããèªæã®éã®ã®ã£ããã¯,売ãäžãã®ææ çãšã³ãžã³ã§ã. - ** ã«ããã³& ããŽã¡ã«ã¹ããŒã®æå€±å«æª:** VSL ã®çµããã«è¿ã¥ã"2ã€ã®é"ãæ±ºå®ããæã«ã¯ç¹å®ã®æãããèšèã§ç¡å¹æ§ã®ã³ã¹ããèšç®ããŸã:$239,000 ã¯ç涯ã«ããã£ãŠäœéæžå°å€±æã å¿èçºäœãè³åäžããã³ã¢ã«ããã€ããŒç ã®ãªã¹ã¯ã®å¢å ã®ããã«è²»ããããŸã. æå€±ã®æ çµã¯è³Œå ¥æ±ºå®ã«ãããå©çæ çµã¿ãäžè²«ããŠäžåã£ãŠãã,VSL ã¯æ±ºçæã«æ£ç¢ºã«é©çšããŸã. - Thaler's Endowment Effect/Risk Reversal: 60 æ¥ä¿èšŒã"ã¯ãã§ã¯ãªãããããã ããæ±ããããš"ãšããŠæ§æãããŠããŠ,å¿ççã«ã³ãããã¡ã³ãã³ã¹ããã»ãŒãŒãã«åæžããŠããŸã. è³Œå ¥ãå®äºãããš,çµæã«é¢ä¿ãªãå¯ä»å¹æã¯éåžžã§è¿æžãåžå°ã«ãã. - Cialdiniã®çšææ§ (人工): äžåã®ãããªé²èЧã®äžã§ããã«æ°å€72ãã26ã«äœäžã,200,000人ã®åŸ æ©ãªã¹ããšåæã«èŠèŽè æ°ãæ°ã (37,942) ã¯å žåçãªéç®åã§ãã. ãããã®æ°åã¯å€éšã§æ€èšŒã§ããªããã,ã»ãŒç¢ºå®ã«ååçã§æé ãããŠãã. - ããŒãã¹ã¹ã¿ããã³ã°ã«ããäºææ§: äŸ¡æ Œãæããã«ãããåã«,5ã€ã®ããŒãã¹ã (ã»ãã©ã©ã®ããã«ãŒããå«ã $1,000ãšã®ãªã·ã£ãžã®æ è¡) å ¥æã«è¿œå ã,çžäºæ§ã®åºæºãéããŠèªèããã矩åãäœãåºããŸã.èŠèŽè ã¯"äžãããã"巚倧ãªäŸ¡å€ã§ããè²·ãç©ã«ãã£ãŠè¿æžããæºåãã§ããŠããŸã. - ãšããã¡ããŒããªããžã®ç©èª (ãã©ã³ãœã³): ãªãã©ã«ã»ãŠã£ã«ãœã³ã®æ¡åŒµçãªã¹ããŒãªãŒ 蚌èšã¯ã¬ãã¥ãŒã§ã¯ãªã å ¬ã®å±èŸ±ãã ããŒã¯å Žã§ç§çãªç Žç¶»ãŸã§ ãã¯ã¿ãŒã»ãã¯ã¿ãŒãšé»è©±ããããŠâ äžé£ã®ææ çæ ã§ã ã¬ã³ããªãŒã. èŠèŽè ã®ææ çäœéšãåæ ã,ã»ã¬ããšæ¶è²»è éã®å¿ççãªè·é¢ã厩ããããã«æ§æãããŠããŸã. > å¥åº·ããŠã§ã«ãã¹åéã§ã¯ãããã®æŠè¡ã¯ 50+ VSLs ã§ã©ã®ããã«æ¯èŒãããŠãããèŠããã§ãã? è€æ°ã®ã¬ãã«ã§åæã«åäœã,åå±€ãç¬èªã®ã¡ãªããã«åºã¥ããŠè©äŸ¡ããããšãéèŠã§ã. ãã®ã·ã¹ãã ã§ã¯,ãã¹ãŠã®èŠçŽ ãæ©èœããŠããããšãããããŸã. ã¬ãã«1ã¯Dr. ã¹ãã£ãŒãã³ã»ã¬ã³ããªãŒèªèº«ã§ã å士ã... ã°ã³ããªãŒã¯æ¬ç©ã®å»è ã . åå¿èç å€ç§å»ã§ ãªã³ã©ã€ã³ã§ã®ååšã å€§å¹ ã«èªããµããªã¡ã³ãäŒç€Ÿã§ãã Gundry MDã®åµèšè ã§ã 圌ã¯ãæ€ç©ãã©ããã¯ã¹ããšãã®ç¶ç·šã®çã®èè ã§ãã,ã©ãããã¹ãã»ã©ãŒãšãªã£ã. ã¡ãã£ã¢ã§ã®åœŒã®åºæŒã¯ Dr. ãªãºãšä»ã®ããã°ã©ã ãèšé²ãããŠããŸã. ãã®ã¬ãã«ã§ã¯,ãã®äººãååšã,圌ã«äžããããè³æ Œãæã£ãŠãããšããçãæå³ã§æš©åšã¯åæ³ã§ãã. Gundryãå®éã«LipoCorpusãåµèšãããã©ãã,ãŸãã¯åœŒã®ååãé¡äŒŒæ§ã¯ãã®ç¹å®ã®è£œåã«çŽæ¥é¢äžããã«äœ¿çšãããŠãããã©ãã㯠VSL ã解決ããŠããªãåé¡ã§ãã,æœåšçãªè³Œå ¥è ã«ãšã£ãŠéèŠãªåºå¥ã§ã. 2 ã¬ãã«ã§ã¯åŒçšãããç ç©¶ããããŸã. JAMAã®äž»åŒµã¯,GLP-1/GIP掻æ§åã«ãã£ãŠé£äºãšéåã®ã¿ãããäœéã67åæžããšè¿°ã¹ãããŠããŠ,決å®çãªçºèŠãšããŠæç€ºãããŠãããã®ã®èè ã幎æãŸãã¯ç¬ç«ããååãå¯èœã«ãã詳现ã«ã¯ä»éããŠããªã. èæœ°çæ£è ã®èª¬æããã"2020幎ã®ã¹ã¿ã³ãã©ãŒãç ç©¶"ã¯,å®éã®å ¬éãããã±ãŒã¹ã¬ããŒãã§ããããšã瀺åããŠãããããªèšè¿°çãªè©³çŽ°ã§æç€ºãããŠããŸãã,éèªã®ã¿ã€ãã«ãèè ã®åå DOI ãŸãã¯å·»çªå·ã¯ãããŸãã. äžçè¥æºé£åã®äºæž¬ãš åŒçšãããäžè¬çãªè¥èæµè¡ç åŠã¯ å®ç©ã§æ€èšŒå¯èœã§ã. Planta Medicaã§çºè¡šãããShoba et al. piperine-curcuminçç©å©çšæ§èª¿æ»ã¯,å®éã®ããŒã¿ã«ãã宿 ç ç©¶ã§ã. æŠèŠã¯æ··åããŠãã.宿 ã®ç ç©¶ãç§åŠçãªæ çµã¿ãåºããã»ã©æ£ç¢ºã«åŒçšãããŠããã,æãåçã«å ·äœçãªäž»åŒµ (äœéæžå°åæ°67xãšGLP-1ã®å¢å 182%) ã¯è¿œè·¡å¯èœãªæ å ±æºããªããã,æé ãããæ°åãèãçã£ãæœåºããããŒã¿ã§ããããã§ã. å士ã... ã¬ããªãšã«ã»ã©ã€ãªã³ã¯æ¬ç©ã®å»åž«ã§ãã äœå®¶ã§ çèäžå¿ã®å»åŠã«é¢ããç ç©¶ã¯ å ¬ã«èšé²ãããŠããŸã. ãã³ã¯å¡©ã®ã¡ã«ããºã ãå ±åçºèŠè ãšã㊠VSL ã«äœçœ®ã¥ããããããšã¯,ããã©ã«ããŒã¹ã®ãã«ã¢ã³æŽ»æ§åãããã¿ã³ãã¯è³ªæåãšçèå¥åº·ã«çŠç¹ãåœãŠãå ¬ã«å©çšå¯èœãªç ç©¶ã«ãã£ãŠè£ä»ããããŠããŸãã. æ€æ»çµæããæããã«ãããŠããªã. ã»ãªãŒãã»ãŽã¡ã¹,ã±ãªãŒã¯ã¯ã©ãŒã¯ãœã³,ã¬ãã«ãŠã£ã«ãœã³ãšã¡ã¬ã€ã³ã»ã±ãªãŒãã¿ããªäœéã®å€åãå ¬éãããŠãã宿 ã®äººç©ã§ãã ãããã®å人ã®ãã¡ã¯èª°ã æããã«æ€èšŒå¯èœãªèšé²ã§ã¯ 圌ãã®çµæãç¹ã«ãªãã³ãŒãã¹ã®ãã®ã ãšèª¬æããŠããŸãã. VSLã¯,ãããã®å人ããã®åœé ãŸãã¯æ€èšŒã§ããªãçŽæ¥çãªåŒçšãæ¬ç©ã®èšŒèšã®ããã«æç€ºã,ãã®ãã¬ãŒã³ããŒã·ã§ã³å šäœã«ãããŠæãéèŠãªä¿¡é Œæ§ã®æžå¿µã衚ããŠããŸã. æš©åšæ§ç¯æŠç¥ã¯ ä¿¡é Œæ§å±€åãšåŒã°ãããã®ã à° à°šà±à°žà°°à°¿à°žà±à°€à±à°à°Šà°¿:å®åšã§æ€èšŒå¯èœãªèªèšŒã®åºç€ã,å¯èŠã§ãäžç¢ºèªãªç§åŠç䞻匵ãäžéå±ã«æ¯ãã.ããã¯åé¢ã§ã¯ã»ãŒç¢ºå®ã«æé ãããæåäººã®æ¿èªãšæå§ç©èªã®äžçªäžå±€ãæ¯æããŸã. åå±€ã¯,ãã®äžã«ãããã®ããæ£åœæ§ãåããŠãã,æ§é å šäœãæãåŒ±ãæ§æèŠçŽ ã®ä¿èšŒãããå åºãªãã®ãšããŠæãããã. ## ç³ãåºã»äŸ¡æ Œåã³ãªã¹ã¯é転 ãã® VSL ã®ãªãã¡ãŒã¡ã«ããºã ãšã¯,ããŒãã¹é£œåæ§ãšçµã¿åãããéå±€å€ã¢ã³ã°ãªã³ã°ã«ãããäºäŸç ç©¶ã§ãã. ç¶ããã $700 ã®ã¢ã³ã«ãŒäŸ¡æ Œã¯,å åã®è²©å£²äžã«"ããã ãã®éé¡ãæ¯æãããšãç³ãåºã人"ãšãã蚌èšã«ãã£ãŠç¢ºç«ãããŠããŠ,æ¯èŒå¯èœãªã«ããŽãªããå®éã®åžå ŽäŸ¡æ Œã¯ã§ã¯ãªã. æšæºçãªãã¬ãã¢ã æ é€ãµããªã¡ã³ãã¯,GLP-1ãµããŒãã«ããŽãªãŒå°å£²ã§æé«ç«¯ã®ããã«ããã $40$80 ã«æäŸãããŸã. $700ã¢ãŒã«ãŒã¯,æ£åœãªã«ããŽãªãŒåºæºã§ã¯ãªã èšè«çãªã€ã³ãã¬ãšããŠæ©èœã,6ç¶ã»ããã®ããã«ããã$49ãšããå®éã®äŸ¡æ Œã¯,æ¯èŒå¯èœãªãµããªã¡ã³ãã³ã¹ããšã»ãŒäžèŽããŠããã«ãããããã,éå¡ãªäŸ¡å€ã衚ãããã«èŠãã. 3éå±€ã®äŸ¡æ Œæ§é ,ãããã $49 6ç¶ (3æ¬è³Œå ¥,3æç¡æ) 2æ¬ã® (1æ¬è²·ã£ãŠ1ã€ç¡æã§), 1ã€ã®2æã® (2æ¬è²·ãããŠ1æ¬éã) ã¯å¹³å泚æå€ãæå€§éã«é«ããããã«èšèšãããæšæºçãªçŽæ¥å¿çéã€ã³ã»ã³ãã£ãã§ã. 6ããã«ãããã¯ã»ãšãã©åžžã«äž»èŠãªå€æç®æšã§ãã,ããŒãã¹ (ã®ãªã·ã£æ è¡æœéžããã³ $1,000 ã»ãã©ã©ã«ãŒããå«ã) ã¯é«é¡ãªæ³šæã«ã®ã¿æ·»ä»ãã,è³Œå ¥è ããã倧ããªã³ãããã¡ã³ãã«åããŠæŒãä»ããäžå¯Ÿç§°çãªã€ã³ã»ã³ãã£ããçã¿åºããŸã. äŸ¡æ Œãå ¬éãããåã«è¿œå ããã5ã€ã®ããžã¿ã«ããŒãã¹ã¯,å€å žçãª"å€ãç©ã¿éãã"æ§é ã«åŸããŸã.äŸ¡æ Œã¯æå®ããããšè³Œå ¥è ã®å éšäŒèšã§ã¯æ°çŸãã«ã®äŸ¡å€ã®ãããã³ããš $49 ãæ¯èŒããŠããŸã. 60æ¥éã®éè¿æžä¿èšŒã¯,ãªãã¡ãŒã®æ§é ã®æãæ£åœãªèŠçŽ ã§ã. è£çµŠåã®60æ¥ä¿èšŒã¯æ¬åœã®æ¶è²»è ä¿è·ã§ãã "質åãªã"ãšããæ çµã¿ãçŽæ¥å¯Ÿå¿å»ç補åã«é¢ãã FTCã¬ã€ãã©ã€ã³ã«äžèŽããŠããŸã. åããŠã®è³Œå ¥è ã«ãšã£ãŠ çµæžçãªãªã¹ã¯ãå€§å¹ ã«åæžããŸã. ããã,ä¿èšŒã¯ç·æ¥æ§äž»åŒµ ("72ç¶ããæ®ã£ãŠããªã") ãšäžŠã¹ãããŠããŠ",æéãåã ä¿è·ãããŠãã"ãšã¬ã©ã¹ã®ã¡ãã»ãŒãžãšã®éã®æ§é çãªç·åŒµãå¿ççã«æŒãä»ããããŠããŸã. ##ããã¯èª°ã®ããã« (ãããŠããã¯äœè ã§ã¯ãããŸãã) ãªãã³ãŒãã¹ã«ãšã£ãŠçæ³ã®è²·ãæãããã£ãŒã«ãšã¯ VSL ã®ã¿ãŒã²ããã·ã°ãã«ã«åºã¥ããŠå¥³æ§ã§ã 35æ³ãã65æ³ã®éã§,ã«ããªãŒå¶éã忥ããã°ã©ã ,éåã¹ã±ãžã¥ãŒã«ããã³ãããããªãŒã¯ã©ã¿ããã®ãµããªã¡ã³ããéããŠäœéæžå°ãé節ã«è©Šã¿ã人. æç¶çãªææã åŸãããªãã®ã§ã. 圌女ã¯ãªãŒã³ãã¯ãšã ãŠã³ãžã£ããèªèã,èå³ãæã¡ãªããã è²»çšãå¯äœçš (ç¹ã«è±æ¯ããã³ãããã"Ozempic face") ãæ³šå°åŒäœéæžå°è¬ã®ç€ŸäŒçæ±ãã«æ¯ããŠããŸãã. ææ çã«èªåã®ã€ã¡ãŒãžã«äžèŽãã身äœãåãæ»ãããšã«æ³šåããŠãã å®éã«æ¥ã𿫿ãçµéšããŠããŸã 圌女ã¯ããŒã±ãã£ã³ã°ã®äž»åŒµã«å¯Ÿã㊠é©åºŠã«æççãªãã®ã® ç¹ã«éå»å€±æãå人ã§ã¯ãªãäœç³»çã«æããŠãã人éã«å¯Ÿã éåžžã«åå¿ãã. 声åªã®ç€ŸäŒèšŒæãš å ±æãã解決ãžã®ç©èªã«åå¿ããŸã ãã®è£œåã«ã€ããŠèª¿æ»ããŠããå Žå,ãã®èª¬æãããªãã®ç¶æ³ã«åèŽãããš,ããŒã±ãã£ã³ã°ã¯ããªãã«ãšã£ãŠç¹å¥ã§ã. ãããŠããã¯ãŸãã« èŽè¡ã æãéå¡ã§ æäœéã®æ€èšŒå¯èœãªäž»åŒµã«ãã£ãŠæåããããšããããšã§ã éèŠãªã°ã«ãŒãã®äººãã¡ã ãã®è³Œå ¥ãäžé©åã ãšèããããŸã. 蚺æããã代è¬ç¶æ (å2ç³å°¿ç ,ç²ç¶è ºçŸæ£,è èç ) ãæ£ã人ã¯"èªç¶ç"æ§é ã«é¢ä¿ãªããã«ã¢ã³ã¬ãã«ãå€åããããšãããµããªã¡ã³ãããšãåã«å»åž«ã«çžè«ãã¹ãã§ã. çŸåšåŠæ¹ãããGLP-1è¬ãæçšããŠãã人ã¯,è£çµŠå€ããããã眮ãæãããè€è£œãããã§ãããšä»®å®ãã¹ãã§ã¯ãããŸãã. äž»ã«æå人ã®èšŒèšã泚ç®ããŠãã人ã¯,ãã® VSL ã®ã¬ãã«ã»ãŠã£ã«ãœã³ãã»ã¬ãŒãã»ãŽã¡ã¹ãªã©ã®çŽæ¥åŒçšã¯ãããã®å人ã®å ¬é声æã«ãã£ãŠè£ä»ãããã,çŽæããŒã±ãã£ã³ã°ã«ããããã®ãããªå±æ§ã®æ³çããã³å«ççå°äœãè°è«ã®äœå°ãããããšãçè§£ãã¹ãã§ãã. æåŸã«,å¥åº·äžã®çç±ããèšåºçã«éèŠãªäœéãæ©ãæžããå¿ èŠããã人㯠å»çåŸäºè ãšäžç·ã«åãå§ããªããã°ãªããŸãã. VSLã®ãµããªã¡ã³ãã§ã¯ãªããã®äž»èŠãªæ çµã¿ã§ã > ãã®åè§£ã¯Intel Servicesã®äžéšã§ãã,ç§ãã¡ã®ç¶ç¶çãªVSLããã³åºåã³ããŒåæå³æžé€šã§ãã. GLP-1ãšäœéæžå°è£çµŠåã®åéã§ã¯åæ§ã®è£œåãæ¢ããŠããå Žåã¯,以äžã®é¢é£åå¥ãèªã¿ç¶ããŸã. ## ããèããã質å Q:ãªãã³ãŒãã¹ã¯è©æ¬ºã§ãã? A: 補åã¯å®éã®æåãå«ãæ¬ç©ã®ãµããªã¡ã³ãã§ ããçš®ã®ä»£è¬çãªå©ç¹ã蚌æãããŠããŸã. ããã,æãåçãªäž»åŒµã®ããã€ãã¯; ç¹å®ã®æåäººã®æ¿èªãå«ã JAMA ã«å²ãåœãŠããã 67x ã®äœéæžå°åæ°ãš Mounjaro ãšç䟡ã¯ç¬ç«çã«æ€èšŒã§ããªã. ææãåççã«ã§ãããã®ãš VSL ã®çŽæã®éã®ã®ã£ããã¯å€§ãããããŸã. ããã¯"è©æ¬º"ã§ãããã©ããã¯,é©çšãããæ³çå®çŸ©ã«äŸåãã.ãããæ¶è²»è ã¯ç°äŸã®äž»åŒµã«å¯ŸããŠçæãæ±ãã¹ãã§ã. Q:ãªãã³ãŒãã¹ã¯æ¬åœã«äœéæžå°ã«åœ¹ç«ã€ã®ã? A:ãã®é æ¹ã«ã¯ç·è¶ããäœãããEGCGããã°ãã·ãŠã ãšãããªã³ã«ããã«ã«ã¯ãã³ãå«ãæåããã,ãã®äžã§ãããããªä»£è¬çãªãµããŒãããã蚌æ ããããŸã. ãã®æåã,ãã®é æ¹ãšæ¬è£œåå ã®æäžé (å ¬éãããŠããªã) ã§1530ãã³ãã®äœéæžå°ã 15ã30æ¥éã«ããã£ãŠçã¿åºããã©ããã¯VSL ã®äž»åŒµã¯ç¹ã«ãªãã³ãŒãã¹ã®ç¬ç«ã§å ¬è¡šãããèšåºè©Šéšã«ãã£ãŠè£ä»ããããŠããªã. Q: ãªãã³ã«ãã¹ãæåããå¯äœçšã¯ããã? A:宣èšããå ¬åŒã«ãããåã ã®æåã¯å žåçãªè£çµŠå€çšéã®å®å šã§ãããšäžè¬çã«èªèãããŠããŸã. [ã«ãã](/ããã°/ã¬ãã¥ãŒ/ ã«ãã-ããã©ã€ - ãããŒã»ããªã㯠- ç·æ§ã®åŒ·åvslåæ) ãšãããªã³ãè¡æ¶²ãèãããç©è³ªãšçžäºäœçšããããšãå¯èœã§ãã. é«éç·è¶æœåºå€ã¯,NIH LiverToxããŒã¿ããŒã¹ã«ãã£ãŠææžåãããå°æ°ã®çäŸã§èèã¹ãã¬ã¹ã«é¢é£ä»ããããŠãã. è¬å€ã«ææãªæ£è ããã¯,䜿çšåã«å»åž«ã蚺ãã¹ãã§ã. Q: LipoCorpus 㯠50æ³ä»¥äžã®å¥³æ§ã«ãšã£ãŠå®å šã§ãã? A:宣èšãããæåã®ã¿ã«åºã¥ããŠ,ãã®é æ¹ã¯æ¬è³ªçã«50æ³ä»¥äžã®å¥³æ§ã«å±éºã§ã¯ãããŸãã. ããã,ç ã£ãŠãããã«ã¢ã³ã·ã¹ãã ãæŽ»æ§åãããšãã䞻匵ã¯èšåºè©Šéšã§æ€èšŒãããŠããªããã,æŽå¹ŽæåŸã®ãã«ã¢ã³ã®å€åã«ã¯ããã©ã«ããã³æ€ç©è£çµŠå€ãå®å šã«è§£æ±ºããå¯èœæ§ããªãè€éãªåé¡ããã. 䜿çšåã«å»åž«ã®çžè«ã¯ãå§ãã§ã. Q: LipoCorpus 㯠Ozempic ã Mounjaro ãšã©ãæ¯èŒãããŸãã? A:Ozempic (ã»ãã°ã«ãŒãã) ããã³ Mounjaro (ãã£ã«ãŒãããŒã) ã¯,é«ç¹ç°æ§ã®ãã GLP-1ããã³GIPå容äœã«çŽæ¥çµåããåŠæ¹è¬å€ã§ãã. äœéæžå°ã«å¯Ÿããèšåºçæå¹æ§ã¯,è€æ°ã®å€§èŠæš¡ã©ã³ãã åãããå¶åŸ¡è©Šéšã§èšé²ãããŠããŸã. æ é€çŽ åé§äœã«ãã£ãŠ ãã®ãã«ã¢ã³ã®çç£ãåºæ¿ãããšäž»åŒµãã ãªãã³ãŒãã¹ã¯,æåŸ ããã广ã®å€§ããã¯ã¯ããã«äœãæ ¹æ¬çã«ç°ãªãä»çµã¿ã§ã. è£çµŠå€ã¯ã ã³ãžã£ãããã"匷åã匷åºã§ãã"ãšãã VSL ã®äž»åŒµãå ¬è¡šãããèšåºèšŒæ ãè£ä»ããŠããŸãã. Q:ãã³ã¯å¡©ã®ããªãã¯ãšã¯äœã Dr. Gundryã¯å®£äŒãã? A: "ãã³ã¯å¡©ã®ããªãã¯"ãšã¯ VSL 㮠販売æ ã§ ãã¿ã·ãŠã ãšãã°ãì (ãã³ã¯ã®ããã©ã€æµ·ã«å±ããŠãã) ã,ç·è¶ãšãã¹ã氎溶åã³ã©ãŒã²ã³ããã³ã«ã¡ãªãã¯-ãããªã³ãšå ±ã«æ¶è²»ããŠããŸã. ç©èªã¯ãããèšåºç ç©¶ã«ãã£ãŠçºèŠãããèªè£œã¬ã·ããšããŠäœçœ®ã¥ããŠããŸãã,販売ãããŠããæçµè£œåã§ãããªãã³ãŒãã¹ã¯ èªå® äœãã®æºåã§ã¯ãªã補é ã®ã«ããã¹ã«ã§ã. Q: ãªãã³ã«ãã¹ã®å¹æãèŠãã®ã«ã©ããããæéãããããŸãã? A: VSL ã®äž»åŒµçµæã¯24æé以å ã«å§ãŸã,10ã15æ¥ä»¥å ã§äœéãå€§å¹ ã«æžããããšãæ±ããããŸã. ç¹å®ã®æåã«é¢ããç ç©¶ã瀺åããããã ãã£ã𿻿çãªæé軞ã§ã è£çµŠæã«ãã代è¬å€åã«å¯ŸããçŸå®çãªæåŸ ã¯,éåžžæ°é±ããæ°ã«æã§æž¬å®ãã,1æ¥ã§ã¯ãªãæ°é±éã§ã.ãããŠé£äºã掻åããã³å人çä»£è°¢ç¶æ ã«äŸåããŸã. Q:å»è¬åæ¥çããã®è£œåã«é¢ããç ç©¶ãæå¶ããããšã¯æ¬åœã§ãã? A: VSLã«ã¯ç¹å®ã®æå§ã®ç©èªãå«ãŸããŠããŸã.è¬ sponsor ãåŒçšããéèªæåŠ,çŠæ¢ããã Today Show ã®ã»ã°ã¡ã³ã,ã¯ãã«ãªã£ãçç£è ãªã©ããããŸã. ãããã®åºæ¥äºã®ã©ãã å ¬ã«å ¬éãããèšé²ã«ãã£ãŠè£ä»ããããŠããŸãã. "è¬å€é°è¬"ã®æ çµã¿ã¯,çŽæ¥åå¿å»çããŒã±ãã£ã³ã°ã«ããã確ç«ãããã³ããŒã©ã€ãã£ã³ã°è£ 眮㧠åçã«å¹æçãªçºèŠãæ¢ã«åºãç¥ãããŠããªãçç±ã説æããããã«äœ¿çšãããŠããŸã. 販売æžã«èŒã£ãŠããã®ã¯äºå®ã§ã¯ãªã. ##æçµçãªåæ ãªãã³ãŒãã¹ VSLã¯,çŸåšã®å»çåžå Žã«ããã3ã€ã®åŒ·åãªæµãã®äº€å·®ç¹ã§æŽ»åããæè¡çã«éæãããçŽæ¥å¿çã³ãã©ã€ãã£ã³ã°äœåã§ã:GLP-1è¬åŠã®äž»æµåæ³å,OzempicãšMounjaroã«é¢ããæ¶è²»è ã®åºç¯ãªèªè,ãããŠãããã®å»è¬åã®ã³ã¹ãããã³å¯äœçšãããã¡ã€ã«ã«å¯Ÿããæ·±ãå ¬è¡çäžæº. é³å£°ã¯ æ£ããæºããããŠããªãæ¬åœã®ããŒãºãç¹å®ããŸã. åŠæ¹ãããæ³šå°è¬ã®ãªã¹ã¯ãè²»çšãªãã§ GLP-1 ã®æŽ»æ§åã«ããæ©æµãæã人ã ã«ãšã£ãŠ,æé ãªäŸ¡æ Œã§ã¢ã¯ã»ã¹å¯èœãªä»£è¬æ¯æŽ. 説åŸåã®ããã±ãŒã¹ã äœã£ãŠããŸã ãã®æ çµã¿ã¯ ããªãä¿¡é Œæ§ã®é«ããã®ã§ å€§èŠæš¡ã§åæ©ã¥ãããã芳客ã«å±ããŸã ç§å¯è£ã®ç§åŠã¯ Dr. è¥æºã®çã®æµè¡ç åŠãšã¬ã³ããªãŒã¯ ãã®æ ¹æ ã確ç«ã ããã«åºã¥ããŠé©ãã¹ã䞻匵ãäœãããŠããŸã VSLã®åŒ±ç¹ã¯,忥çã«æãéèŠãªãã®ã§ããã. ã¬ã¹ãã«ã»ãŠã£ã«ãœã³,ã»ã¬ãŒãã»ãŽã¡ã¹ãªã©ã«èµ·å ããæå人ã®èšŒèšã¯ å人çãªæ¯æãæå³ããç¹ç°æ§ãçŽæ¥æ§ã衚ããŠããŸãã ãããã®è©äŸ¡ã®è£ä»ãã«ã¯ å ¬çã«å©çšå¯èœãªèšé²ã¯ãããŸãã. åŒçšãããç¹å®ã®èšåºããŒã¿,äœéæžå°åæ°67x,ã«ãªãŠã ããGLP-1ã®182%å¢å ,ãã°ãã·ãŠã ã®144% GIPã®å¢å ã¯ãããã®ãã©ã¡ãŒã¿ãå«ãå ¬éããåçŽå¯©æ»è©Šéšã«è¿œæº¯ã§ããªã. è¬å€ã®æäžé㯠å容äœã¬ãã«ã®æçç©è³ªãè€è£œã§ãããšãã äž»èŠãªä»çµã¿ã¯ ç§åŠæç®ã§ã¯ çŸåšè§£æ±ºã§ããªãå¯èŠæ¹åæ§å¹æãšåçãªç䟡æ§ã®éã®ã®ã£ããã衚ããŠããŸã æœåšè³Œå ¥è ã«ãšã£ãŠæãæçšãªåææ çµã¿ã¯,LipoCorpusã®å®£èšãããé æ¹äžã®æåãç¡å¹ã§ã¯ãªãããšã§ãã,äžéšã®ç©è³ªã«ã¯é©åºŠã«ä»£è¬ããã³æçæ§å¹æããããšããæ£åœãªèšŒæ ããããŸã. è¬ã¯å¥åº·ãªæäººã«ãšã£ãŠå žåçãªæäžã§å±éºã§ããå¯èœæ§ãäœã. ãããäžå¯èœãªã®ã¯ 1524ãã³ãã®äœéã15ã30æ¥éã§æžããåºãããšã§ã VSLã¯"æ¥ã«1é ã ãæåããããšã§ ã¢ãŠã³ãžã£ããšåçã®æ¿åºŠã§çŽæããŸã. è³Œå ¥è ãå¿ èŠãªã®ã¯ ãã®ç¹å®ã®çµæãªã ããã¯é©åãªããŒã«ã§ã¯ãããŸãã. æ¶è²»è ãå®éã®æŽ»æ§æåãåããåççãªäŸ¡æ Œã§ä»£è¬è£å©å€ãæ¢ã,çŸå®çæåŸ ã«å¿çšããããªã ãã®é æ¹èªäœã¯ãã®åšãã®ãããããã ããå®ããã§ããã. è¬å€ã®GLP-1çŸè±¡ãè£çµŠåå šäœã®æ¯è²ãå€åãããçšåºŠã§ã. ãã®ç ç©¶ã§ã¯,ãã®çš®ã®é£åã¯1ã€ã®çš®é¡ããç°ãªããã®ãšèããããŠããŸã. 代è¬ã飿¬²,ãããã¯"ç±åè¬"ãäžå¿ã«è²©å£²ãããŠãã補å㯠ä»ã§ã¯ãã«ãŒãã¿ã€ããæåã«ãªã£ããã«ã¢ã³è»žã®åšãã«åé 眮ãã ã€ã³ã¯ã¬ãã³è£œå€åŠã®èšåºçšèªåºã䜿ã£ãŠ ç§åŠçãªè³ªæãäžããã äž»èŠãªäž»åŒµã¯æ¥çã¯åžžã«çŽæããŠãããã®ã§ã. 説åŸåã®ãã建ç¯ã®æŽç·Žã¯å®åšã,æ¶è²»è ã¯åæ§ã«æŽç·Žãããèªæžãã«å€ãã. ãã®åå¥ã¯ Intel Servicesã®äžéšã§ VSLãš ad-copy ã®åæãç¶ç¶çã«æäŸããŠããŸã. äœéæžå°è£çµŠå€ãGLP-1代æ¿ã¹ããŒã¹ã«äŒŒã補åãæ¢ããŠããå Žåã¯,èªã¿ç¶ããŸã. å 責:ãã®èšäºã¯ç ç©¶ããã³æè²ç®çã®ã¿ã§ã. å»ç,æ³åŸ,éèã«é¢ããå©èšã§ã¯ãããŸãã.ãŸã補åã補é è ãšã®é¢é£ããããŸãã. å¥åº· ä¿éº ã éé ã® åé¡ ã« ã€ã ㊠ã¯,åžžã« æèœ 㪠ãããã§ãã·ã§ãã« ãšçžè« ãã.
Comments(0)
No comments yet. Members, start the conversation below.
Related reads
- DISreviews
ãªãŒã³ãããããšåºååæ
Facebookã®åç»ã ç»é¢ã®äžå€®ã«åããªãã ãã女æ§ãå·ããç¶æ ãæ¢ãŸã質åãèãã®ã§ã ãªãã»ãªãŒãã»ãŠã£ãªã¢ã ãºã 1ã€ã®å°ããªãŒãªãŒã® ãã¥ãŒããé£ã¹ãŠ...
Read
reviewsBurnSlim VSLãšåºååæ
ãããªè²©å£²ã®éå¹ã®2ç§éã« ããç¹å®ã®ãªããŒãªãã¯ãªè³ãã 眮ãããŠããŸã ã±ãªãŒã»ã¯ã©ãŒã¯ãœã³ã 1 ãã¥ãŒãã®ãŒã©ãé£ã¹ãŠ 68æ¥ã§ 60ãã³ãç©ãããš èŠèŽè ã«äŒããããŠããŸã
Read
reviewsãªãã»ãã€ã ã¬ãã¥ãŒãšåºåã®åè§£:ç ç©¶ååèŠæ¹
å£²ãææçŽã¯ ã»ãŒæ ç»åãããã·ãŒã³ã§å§ãŸããŸã äžççã«ç¥ãããæå人ã "ãŽã©ãŒã°"ã®ããã¥ã¡ã³ã¿ãªãŒã€ã³ã¿ãã¥ãŒã«åº§ã£ãŠ å€éååŒãèšè¿°ããŠããŸã...
Read